'''Trimebutine''' is a drug with [[antimuscarinic]] and weak [[mu opioid receptor|mu]] [[opioid]] [[agonist]] effects.<ref>Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. ''Journal of Pharmacobiodynamics''. 1990 Jul;13(7):448-53. {{PMID|1963196}}</ref> The [[maleic acid]] salt of trimebutine is marketed under the [[trademark]] of '''Debridat''', '''Recutin''', '''Polybutin''',<ref>Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC–MS/MS method. ''Clinica Chimica Acta''. 2007 Jan;375(1-2):69-75. {{PMID|16854404}}</ref> or '''Modulon''' for treatment of [[irritable bowel syndrome]] and other gastrointestinal disorders.  The major product from [[drug metabolism]] of trimebutine in human beings is [[nortrimebutine]],<ref>F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. ''The Journal of Pharmacology and Experimental Therapeutics'' 1999;289:1391–1397. {{PMID|10336531}}</ref> which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the [[migrating motor complex]] in the digestive tract.<ref name="Hiyama-2009">{{Cite journal  | last1 = Hiyama | first1 = T. | last2 = Yoshihara | first2 = M. | last3 = Tanaka | first3 = S. | last4 = Haruma | first4 = K. | last5 = Chayama | first5 = K. | title = Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. |url=http://onlinelibrary.wiley.com/store/10.1111/j.1440-1746.2009.05780.x/asset/j.1440-1746.2009.05780.x.pdf?v=1&t=hl2d93pj&s=53675e2a2742207be72071a180997b9023ea13ec | journal = J Gastroenterol Hepatol | volume = 24 | issue = 4 | pages = 537-46 |date=Apr 2009 | doi = 10.1111/j.1440-1746.2009.05780.x | PMID = 19220673 }}</ref> Both Trimebutine and its metabolite are commercially available.
